UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. Its core products include Cimzia for rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, and Crohn's disease; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. The company also offers Zyrtec and Xyzal for allergy. Its product pipeline includes Evenity for the treatment of osteoporosis; bimekizumab for psoriasis, psoriatic arthritis, and ankylosing spondylitis diseases; dapirolizumab pegol for systemic lupus erythematosus; padsevonil for highly drug resistant epilepsy; seletalisib for Sjögren's syndrome; rozanolixizumab for immune thrombocytopenia; UCB4144/VR942 for asthma; UCB6673, UCB7858, and UCB0159 for the treatment of neurology; and UCB3491 and UCB0599 for bone treatment. UCB SA was founded in 1928 and is based in Brussels, Belgium.

This company cross-lists their shares on a U.S. stock exchange. See the related U.S. symbol UCBJF.

This company has ADRs that trade in the U.S. as the symbol UCBJY.This company has cross-listed shares that trade in the U.S. as the symbol UCBJF.

88.52 EUR
As of 01/14/2022

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Belgium
Country of incorporation:  Belgium
IPO date:  01/03/2000
Stock exchange:    Nyse Euronext - Euronext
Exchange country:   Belgium
Market cap:   16,713,637,888 EUR
Current dividend yield:   1.41%
Sedol:      5596991

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy